Search results for " DIABETES MELLITUS"

showing 10 items of 309 documents

Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabet…

2018

Este artículo se encuentra disponible en la siguiente URL: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-documento-consenso-sociedad-espanola-arteriosclerosis-S0214916818300846 This is the pre-peer reviewed version of the following article: Ruiz-García, A., Arranz-Martínez, E., Morón-Merchante, I., Pascual-Fuster, V., Tamarit, JJ., Trias-Villagut, F. et al. (2018). Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. Clínica e Investigación en Arteriosclerosis, vol. 30, supl. 1 (julio), pp. 1-19, which has been published in final form …

Blood pressure controlmedicine.medical_specialtyHipertensión.FarmacologíaEnfermedad cardiovascularDisease030204 cardiovascular system & hematologyDiabetes - Farmacoterapia.Enfermedades cardiovasculares - Factores de riesgo - Tratamiento.Diabetes - Chemotherapy.03 medical and health sciencesTratamiento médicoCardiovascular system - Diseases - Risk factors - Treatment.0302 clinical medicineDiabetes mellitusHypertension.MedicinePharmacology (medical)Lipid controlHypoglycemic drugs030212 general & internal medicineIntensive care medicineInhibidores de agregación plaquetariabusiness.industryHypertriglyceridemiaType 2 Diabetes Mellitusnutritional and metabolic diseasesArteriosclerosismedicine.diseaseDiabetes mellitus tipo 2Cardiology and Cardiovascular Medicinebusiness
researchProduct

SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF-α

2015

AbstractCeramide regulates several different cellular responses including mechanisms leading to apoptosis. Serum- and glucocorticoid-inducible protein kinase (SGK)-1 is a serine threonine kinase, which activates survival pathways in response to stress stimuli. Recently, we demonstrated an anti-apoptotic role of SGK-1 in human umbilical endothelial cells treated with high glucose. In the present study, since ceramide induces apoptosis by multiple mechanisms in diabetes and its complication such as nephropathy, we aimed to investigate whether SGK-1 may protect even against apoptosis induced by ceramide in kidney cells. Human embryonic kidney (HEK)-293 cells stable transfected with SGK-1 wild …

Cancer ResearchProgrammed cell deathCeramideSettore MED/09 - Medicina InternaDIABETES MELLITUSImmunologyProtein Serine-Threonine KinasesTNF ALPHABiologyCeramidesKidneyTransfectionImmediate-Early ProteinsSettore MED/13 - EndocrinologiaCellular and Molecular Neurosciencechemistry.chemical_compoundHumansSettore MED/49 - Scienze Tecniche Dietetiche ApplicateProtein kinase ASettore MED/04 - Patologia GeneraleSerine/threonine-specific protein kinaseTumor Necrosis Factor-alphaCERAMIDEKinaseHEK 293 cellsKidney metabolismCell BiologyLipid signalingINSULINAPOPTOSIS3. Good healthCell biologyHEK293 CellschemistryINSULIN CERAMIDE DIABETES MELLITUS TNF ALPHA APOPTOSISOriginal ArticleCell Death & Disease
researchProduct

Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to poor response to systemic therapy. Therefore, developing strategies for early diagnosis of resectable PC is critical for improving survival. Diabetes mellitus is another major public health problem worldwide. Furthermore, diabetes can represent both a risk factor and a consequence of PC: nowadays, the relationship between these two diseases is considered a high priority for research. New-onset diabetes can be an early manifestation of PC, especially in a thin adult without a family history of diabetes. However, even if targeted screening…

Cancer Researchmedicine.medical_specialtyConsensusReviewDiseaseMedical OncologySystemic therapyNOconsensus; diabetes; early diagnosis; hyperglycaemia; pancreatic carcinoma; Consensus; Humans; Medical Oncology; Diabetes Mellitus; Pancreatic Neoplasms; PhysiciansDiabetes mellitusPancreatic cancerPhysiciansmedicineDiabetes MellitusHumansFamily historyRisk factorLS4_3Intensive care medicinediabetes pancreatic carcinoma early diagnosis consensus hyperglycaemiadiabetespancreatic carcinomabusiness.industryPublic healthmedicine.diseasePancreatic NeoplasmsOncologyPosition paperbusinesshyperglycaemiaearly diagnosis
researchProduct

[Diagnosis of coronary microvascualar dysfunction in diabetic patients with cardiac syndrome X: comparison by current methods].

2013

The study population included 208 patients with chest pain and uninjured coronary arteries that we split into two populations: diabetics (72 patients) and non-diabetics (136 patients). We split patients with chest pain and uninjured coronary arteries that had a myocardial scintigraphy into two populations: patients with positive scintigraphy and negative. We calculated, on angiographic images of each patient, stored on suitable digital supports, Timi Frame Count (TFC), Myocardial Blush Grade (MBG) and Total Myocardial Blush Score (TMBS) using the protocol described by Gibson and Yusuf. On the basis of Yusuf's experience we imagined a new index: the Total Timi Frame Count as the sum of the t…

Cardiac syndrome X chest pain coronary angiography diabetes mellitus microcirculation myocardial scintigraphyChest PainMicrocirculationReproducibility of ResultsCoronary DiseaseCoronary AngiographySeverity of Illness IndexElectrocardiographyPredictive Value of TestsRisk FactorsCoronary CirculationExercise TestHumansEmergency Service HospitalRadionuclide ImagingBlood Flow VelocityDiabetic AngiopathiesMicrovascular Angina
researchProduct

Bicycling to school improves the cardiometabolic risk factor profile:a randomised controlled trial

2012

Objectives To investigate whether bicycling to school improves cardiometabolic risk factor profile and cardiorespiratory fitness among children. Design Prospective, blinded, randomised controlled trial. Setting Single centre study in Odense, Denmark Participants 43 children previously not bicycling to school were randomly allocated to control group (n=20) (ie, no change in lifestyle) or intervention group (ie, bicycling to school) (n=23). Primary and secondary outcome measures Change in cardiometabolic risk factor score and change in cardiorespiratory fitness. Results All participants measured at baseline returned at follow-up. Based upon intention-to-treat (ITT) analyses, clustering of car…

Cardiometabolic riskmedicine.medical_specialtybusiness.industryFactor scoreResearcheducationType 2 Diabetes MellitusCardiorespiratory fitnessGeneral MedicineDiseasePeer reviewlaw.inventionRandomized controlled trialchildrenlawcommutingPhysical therapycardiometabolicMedicinerisk factorsbicyclingPublic HealthbusinessTrial registration
researchProduct

1267 HSP70-2 polymorphism as a risk factor for carotid plaque rupture and cerebral ischaemia in old type 2 diabetes-atherosclerotic patients.

2005

Patients with type 2 diabetes mellitus (NIDDM) are at risk for macrovascular disease complications, such as myocardial infarction (MI) or stroke from plaque rupture. Cytokines play a key role in plaque vulnerability. IFN-gamma inhibits collagen synthesis thereby affecting plaque stability. High IL-6, TNF-alpha, and dyslipidemia are risk factors for thrombosis. Abnormal increments of HSP70 in atherosclerotic plaques might lead to plaque instability and rupture caused by chronic inflammation, which up-regulates the expression of pro-inflammatory cytokines (IL-6 and TNF-alpha) in human monocytes. Studies of a polymorphic PstI site lying in the coding region at position 1267 of the HSP70-2 gene…

Carotid Artery DiseasesMaleAgingmedicine.medical_specialtyGenotypeArteriosclerosisType 2 diabetesGastroenterologyBrain IschemiaInterferon-gammaGene FrequencyRisk FactorsInternal medicinemedicineHumansCarotid StenosisHSP70 Heat-Shock ProteinsMyocardial infarctionRNA MessengerAllelesTriglyceridesMacrovascular diseaseAgedGlycated HemoglobinRupturePolymorphism Geneticbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaType 2 Diabetes MellitusOdds ratioCholesterol LDLMiddle Agedmedicine.diseaseThrombosisEndocrinologyCarotid ArteriesDiabetes Mellitus Type 2Relative riskFemalebusinessDyslipidemiaDevelopmental BiologyMechanisms of ageing and development
researchProduct

Agent +014 health program: gamification applied to the education of adolescents with diabetes according to the Precede-Proceed model and from a salut…

2021

Resumen Objetivos: la diabetes mellitus tipo 1 es una enfermedad crónica que suele debutar en la infancia y necesitar formación a lo largo para dar respuesta a los cambios producidos en todas las etapas vitales. El objetivo de esta investigación es desarrollar un programa de educación para la salud, siguiendo el modelo Precede-Procede y desde una perspectiva salutogénica atendiendo a las necesidades de la población adolescente y que incluya la gamificación como estrategia educativa. Materiales y métodos: la primera fase es investigación mixta, cuantitativa y cualitativa y combina diferentes instrumentos para la recogida de información. Los participantes son adolescentes con dicho diagnóstic…

Community and Home CareHealth (social science)juegoHealth Policydiabetes mellitus tipo 1EspañaPublic Health Environmental and Occupational HealthEspanhaHealth Professions (miscellaneous)Health educationdisease managementEducação em saúdeSpainmanejo da doençajogoEducación en saludmanejo de la enfermedadplaytype 1 diabetes mellitus
researchProduct

Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical …

2022

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract. GEP-NETs incidence has been steadily increasing over the past decades, in parallel with the increasing incidence of the metabolic syndrome (MetS). It is not yet fully known whether the MetS components (such as obesity, dyslipidemia and type 2 diabetes) could be involved in the etiology of GEP-NETs or could influence their outcomes. In this review, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Endocrinology…

ConsensusSettore MED/06 - Oncologia MedicaGEP-NET progressionMetabolic disordersHematologyMedical OncologyMetabolic syndromeNOGEP-NET survivalPancreatic NeoplasmsNeuroendocrine Tumorsgastroenteropancreatic neuroendocrine tumors; gep-net progression; gep-net survival; metabolic disorders; metabolic syndrome; consensus; humans; medical oncology; diabetes mellitus; type 2; intestinal neoplasms; neuroendocrine tumors; pancreatic neoplasms; stomach neoplasmsOncologyGEP-NET progression; GEP-NET survival; Gastroenteropancreatic neuroendocrine tumors; Metabolic disorders; Metabolic syndromeDiabetes Mellitus Type 2Stomach NeoplasmsIntestinal NeoplasmsDiabetes MellitusHumansLS4_3Gastroenteropancreatic neuroendocrine tumorsType 2
researchProduct

Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients

2022

nessuno

Diabetes Mellitus Type 1EndocrinologyNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismInternal MedicineHumansObesityCardiometabolic risk Diabetes mellitus type 1 Metabolic syndrome Nonalcoholic Nonalcoholic fatty liver disease Obesity SteatohepatitisJournal of Diabetes and its Complications
researchProduct

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations fr…

2022

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have …

Diabetes Mellitus Type 2Cardiovascular DiseasesGlucagon-Like Peptide 1HumansHypoglycemic AgentsAlgorithm Cardiovascular outcomes trials GLP-1 receptor agonists Treatment Type 2 diabetes mellitusLiraglutideCardiology and Cardiovascular MedicineAlgorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.Glucagon-Like Peptide-1 ReceptorInternational Journal of Cardiology
researchProduct